Boston Forum: Merger Control & Competition in Life Sciences

Goodwin partners Arman Oruc, Sarah Jordan, and Stephen Mavroghenis are excited to invite you to join us in-person for an engaging discussion on antitrust in life sciences transactions, navigating global merger control investigations and what to do when your deal hits a regulatory brick wall. We’ll cover the latest trends in early-stage deals, strategies for surviving antitrust scrutiny, and stories from deals that didn’t make it through.

Special guests Abbas Kazimi, Chief Executive Officer at Nimbus Therapeutics, Jana Gold, Principal at JanaGold Law (former Head of Legal of Maze Therapeutics), and Jeff Stoll, Partner, Deal Advisory & Strategy at KPMG, will join to speak on a fireside chat and panel discussion. Don’t miss this chance to gain practical insights, ask the tough questions, and discuss what’s to come over cocktails, register below!

CLE credit will be offered for CA, NY, NJ, and PA (pending approval).

Agenda

Fireside Chat | 3:30 – 4:15 PM ET

• Abbas Kazimi, Chief Executive Officer, Nimbus Therapeutics
• Arman Oruc, Partner, Co-Chair, Antitrust + Competition, Goodwin

Panel Discussion | 4:30 – 5:30 PM ET

• Jana Gold, Principal, JanaGold Law (former Head of Legal of Maze Therapeutics)
• Sarah Jordan, Partner, Antitrust + Competition, Goodwin
• Stephen Mavroghenis, Partner, Antitrust + Competition, Goodwin
• Arman Oruc, Partner, Co-Chair, Antitrust + Competition, Goodwin
• Jeff Stoll, Partner, Deal Advisory & Strategy, KPMG

Cocktails & Bites | 5:30 – 7:30 PM ET